On March 3, 2022, ArrePath, an anti-infective drug discovery company addressing drug resistant infections, announced it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR). The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures. ArrePath President and CEO Dr. Lloyd Payne stated the funding will enable the advancement of initial leads and expansion of discovery efforts, as well as the enhancement of ArrePath's imaging platform and the application of machine learning in the discovery of new drugs to address critical global health challenges.

A Wilson Sonsini Goodrich & Rosati team including Mark Solakian, Amanda Creedon, and Reilly Clark advised ArrePath on the transaction.

For more information, please see ArrePath's press release.